Evaluación positiva de medicamentos: septiembre, octubre y noviembre 2017

García Luque, A; Puerro Vicente, M; Sánchez López, P; López Morán, MJ.
Sanid. mil ; 74(1): 26-31, ene.-mar. 2018.
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-173104

Documentos relacionados

  1. Evaluación positiva de medicamentos: diciembre 2017, enero y febrero 2018
  2. Accelerated drug approval: Meeting the ethical yardstick.
  3. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information.
  4. Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?
  5. An open science pathway for drug marketing authorization-Registered drug approval.
  6. Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval.
  7. Health Canada's use of priority review status for drugs for unmet needs.
  8. Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan.
  9. Recent Use of Pediatric Extrapolation in Pediatric Drug Development in US.
  10. Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020.